

---

1 **Engineered periosteum-diaphysis substitutes with biomimetic structure**  
2 **and composition promote the repair of large segmental bone defects**

3 Lili Yu<sup>a,1</sup>, Qiang Wei<sup>a,1</sup>, Jiaying Li<sup>a</sup>, Huan Wang<sup>a</sup>, Qingchen Meng<sup>a</sup>, En Xie<sup>a</sup>, Zexi Li<sup>a</sup>,  
4 Kexin Li<sup>a</sup>, Wenmiao Will Shu<sup>b</sup>, Junxi Wu<sup>b</sup>, Lei Yang<sup>a,c</sup>, Yan Cai<sup>a,\*\*\*</sup>, Fengxuan Han<sup>a,\*\*</sup>,  
5 Bin Li<sup>a,\*</sup>

6  
7 <sup>a</sup> College of Chemistry, Chemical Engineering and Materials Science, Orthopedic  
8 Institute, Department of Orthopaedic Surgery, The First Affiliated Hospital, Suzhou  
9 Medical College, Soochow University, Suzhou, Jiangsu, China

10 <sup>b</sup> Department of Biomedical Engineering, University of Strathclyde, Glasgow, G1 1QE,  
11 UK

12 <sup>c</sup> Center for Health Sciences and Engineering (CHSE), School of Health Sciences and  
13 Biomedical Engineering, Hebei University of Technology, Tianjin, China

14  
15 <sup>1</sup> Lili Yu and Qiang Wei contributed equally to this work and shared the first authorship.

16  
17 \* Corresponding author.

18 \*\* Corresponding author.

19 \*\*\* Corresponding author.

20  
21  
22 \* Corresponding to:

23 Prof. Bin Li, Rm 201 Bldg Jiwu, Soochow University (North Campus), 178 Ganjiang  
24 Rd, Suzhou, Jiangsu 215007, China

25 Tel. & Fax: (+86) 512-6778-1163

26 E-mail addresses: binli@suda.edu.cn (Bin Li), fxhan@suda.edu.cn (Fengxuan Han),

27 wcy65168299@163.com (Yan Cai).

31 **Abstract**

32       The repair of large segmental bone defects remains a big challenge due to limited  
33 self-healing capacity of bone. Digging into the structure and composition of natural long  
34 bone let us realize that the periosteum cambium on the surface of diaphysis plays a crucial  
35 role in bone repair. In this study, we explored the feasibility of using a tissue-engineered  
36 periosteum-diaphysis substitute to repair the large segmental bone defects. To create an  
37 artificial periosteum cambium, bone marrow mesenchymal stem cells (BMSCs) and  
38 endothelial progenitor cells (EPCs) were co-cultured on electrospun silk fibroin (SF)  
39 fibrous membranes for mimicking the cellular composition and microstructure of  
40 cambium layer of the native periosteum. These SF membranes supported the adhesion  
41 and proliferation of both BMSCs and EPCs. In addition, we found that a 1:1 ratio of  
42 BMSCs and EPCs supported osteogenesis and angiogenesis optimally. This biomimetic  
43 periosteum layer was integrated with artificial diaphysis made of tubular SF scaffolds to  
44 construct a biomimetic periosteum-diaphysis substitute. Animal studies confirmed that  
45 the biomimetic periosteum-diaphysis substitutes promoted the repair of critical-size bone  
46 defects of rabbit radius. Furthermore, the transplanted biomimetic periosteum-diaphysis  
47 substitute could prevent the growth of fibrous tissues in the bone defect, and thus reduce  
48 the occurrence of nonunion. This study described a promising tissue engineering strategy  
49 for the repair of large segmental bone defects.

50

51 **Keywords:** Silk fibroin; Electrospun membrane; Periosteum cambium; Diaphysis;

52 Bone repair

53

54 **1. Introduction**

55 More than two million Americans suffer from large bone defects annually, and ~5%  
56 of them require medical intervention to heal [1]. Currently, the treatment of large bone  
57 defects remains a tough challenge, largely due to hypoxia and nutrient deficiency [2]. The  
58 diaphysis, main portion of the bone, will face more severe nutritional deficiencies than  
59 other parts of long bone after large segmental bone injury, which make its repair a big  
60 challenge. It is reported that 5-10% of patients with large segmental bone defects will be  
61 disabled due to the delayed union or nonunion of the broken fragments [3]. Current  
62 treatments involve autologous and allogeneic bone transplantation. However, the shortage  
63 of donor, ethical concerns, and the worrying survival of transplants limit the effectiveness  
64 of these treatments [4, 5]. In the past decade, many attempts have been made in bone  
65 tissue engineering to promote the repair of bone defects with scaffolds in combination  
66 with osteoprogenitor cells. However, these engineered scaffolds show suboptimal  
67 curative effect due to the lack of progenitor cells and vascular network, which often leads  
68 to tissue necrosis [6].

69 The long bone consists mainly of the diaphysis and periosteum covering the surface.  
70 In the traditional management of large bone defects, the focus was on the repair of  
71 diaphysis, while the importance of periosteum was often overlooked. However, recent  
72 studies demonstrated that the removal of bone marrow progenitor cells had a negligible  
73 effect on bone regeneration, while the loss of periosteum led to a 73% reduction in new  
74 bone formation [7]. The periosteum is a fibrous connective tissue membrane which has

75 two unique layers. The outer fibrous layer is mainly composed of fibroblasts and collagen  
76 fibers which provide support and protection for the periosteum and bone. The inner layer,  
77 also known as cambium layer, contains H-type vascular endothelial cells and various  
78 progenitor cells that are directly associated with osteogenesis. The cambium layer also  
79 provides essential nutrients for bone regeneration [8]. Thus, the remodeling of periosteum  
80 is increasingly being considered as a critical component in the treatment of severe  
81 fractures and the prevention of nonunion.

82         Given this change in direction, tissue-engineered periosteum is increasingly being  
83 used to repair large segmental bone defects [9]. Current tissue-engineered periosteum  
84 scaffolds are made of acellular dermis, cell sheets, hydrogels, electrospun membranes,  
85 and porcine small intestinal submucosa. However, these structures fail to replicate the  
86 role of promoting osteogenesis and angiogenesis compared to the natural periosteum.  
87 For example, some bioactive factors were directly added to these materials [10]. However,  
88 these attempts often led to adverse outcomes such as inflammation and immune responses  
89 [11, 12], excessive, or ectopic osteogenesis [13]. Another strategy is to use the artificial  
90 periosteum as a vehicle to deliver drugs to enhance its osteogenic potential [14, 15]. This  
91 strategy has improved the solubility and bioavailability of poorly soluble drugs to a  
92 certain extent, but there are still limitations such as clearance by the body, insufficient  
93 targeting efficiency, poor carrier safety and tissue permeability. Therefore, it is an urgent  
94 need to develop an artificial periosteum that mimics the natural cambium layer providing  
95 cellular components and necessary growth factors for osteogenesis and angiogenesis.

96           The unsatisfactory results of periosteum tissue engineering partly attribute to the  
97 lack of cellular components. Bone marrow mesenchymal stem cells (BMSCs) are the  
98 most widely used cells in bone tissue engineering, which have the potential to  
99 differentiate into osteoblasts [16, 17]. Endothelial progenitor cells (EPCs) have been  
100 shown to promote bone healing due to their excellent pro-angiogenic capacity. Studies  
101 have shown that the co-culture of BMSCs and EPCs can synergistically promote  
102 osteogenesis and angiogenesis [18], however, the optimal ratio between the two types of  
103 cells remains disputed and needs to be further confirmed experimentally.

104           Silk fibroin (SF) is a natural fibrin extracted from the cocoons of silkworm and has  
105 excellent biocompatibility, biodegradability, and good mechanical properties [19]. It  
106 demonstrates tunable mechanical properties comparable to various tissues, making it a  
107 suitable material in bone tissue engineering. Electrospinning is a simple and widely  
108 available technology that can be used to prepare fibrous membrane with a microstructure  
109 similar to the natural periosteum [20, 21]. In addition, large segmental bone repair also  
110 requires a scaffold to maintain the structural stability. The diaphysis of long bone is  
111 hollow inside, with a porous tubular structure. Directional freeze drying is a technology  
112 for the fabrication of scaffolds with directional pores that could mimic the microstructure  
113 of diaphysis [22]. This technology enables the creation of tubular SF structures with  
114 directional pores by means of suitable molds. As reported previously, scaffolds with  
115 directional pores are more conducive to the infiltration and migration of surrounding cells,  
116 the exchange of nutrients and metabolic wastes, and the deposition of extracellular matrix

117 [23, 24]. Inspired by the structure of natural long bone, the design of biomimetic bone  
118 substitutes for the promotion of bone repair is now becoming possible.

119 In this study, we developed tissue-engineered periosteum-diaphysis grafts for the  
120 repair of large segmental bone defects. The scaffold is composed of cell-laden SF  
121 electrospun fibrous membranes which mimic the microstructure and cellular composition  
122 of the cambium layer of periosteum. In addition, tubular SF scaffolds with hollow  
123 channels and aligned micropores were prepared by directional freeze-drying to mimic the  
124 natural structure of diaphysis. Firstly, different proportions of BMSCs and EPCs were co-  
125 cultured on electrospun SF membranes and then the optimal ratio of BMSCs and EPCs  
126 was screened for the following experiments. Subsequently, the membranes seeded with  
127 cells (MC) were wrapped around the surface of oriented SF scaffolds to form a combined  
128 periosteum-diaphysis substitute (SFMC). Finally, SFMC grafts were implanted into  
129 segmental bone defects of rabbit radius for assessing the capacity of bone repair (Scheme  
130 1).

131

## 132 **2. Materials and Methods**

### 133 **2.1 Preparation of electrospun SF membranes**

134 Silkworm cocoons (New Silk Road Ltd, China) (6-8 g) were degummed twice with  
135 3 L of 0.4% Na<sub>2</sub>CO<sub>3</sub> solution at 98 °C for 40 min and then dissolved in 9.3 M LiBr (Sigma-  
136 Aldrich, USA) solution. The solution was dialyzed for 72 h (Viskase, MWCO 3500 Da).  
137 The SF solution was frozen overnight at -80 °C and freeze-dried for 72 h. The lyophilized

138 SF was dissolved in hexafluoroisopropanol for electrospinning. The flow rate, voltage,  
139 and distance from the nozzle to the collection device were set as 1 mL/h, 12 kV, and 10  
140 cm, respectively. Electrospun SF membranes were dried overnight at room temperature  
141 to evaporate residual solvent.

## 142 **2.2 Preparation of biomimetic periosteum-diaphysis substitutes**

143 The biomimetic periosteum-diaphysis substitute was prepared by wrapping an  
144 electrospun SF membrane on a tubular SF scaffold. The tubular SF scaffold with oriented  
145 and interconnected pores was fabricated by directional freeze-drying. In brief, the SF  
146 solution was added into silicone molds and frozen by liquid nitrogen. SF scaffolds were  
147 then collected from the silicone molds, treated with 90% methanol for 30 min to induce  
148 the formation of  $\beta$ -sheet structures rendering them insoluble in aqueous solutions.  
149 Electrospun SF membranes were wrapped around SF tubular scaffolds to form the  
150 biomimetic periosteum-diaphysis substitutes.

## 151 **2.3 Characterizations of biomimetic periosteum-diaphysis substitutes**

152 The morphology of electrospun SF membranes and biomimetic periosteum-  
153 diaphysis substitutes was observed by scanning electron microscopy (SEM, S-4800,  
154 Hitachi, Kyoto, Japan). The hydrophilicity of electrospun membranes was analyzed using  
155 a contact angle tester (Kruss, Germany). The mechanical properties of electrospun SF  
156 membranes were determined using a universal testing machine (HY-0580, Shanghai  
157 Hengyi Co., Ltd, China). The tensile modulus of the membranes was calculated according  
158 to the stress-strain curve.

159 *In vitro* degradation of biomimetic periosteum-diaphysis substitutes was evaluated  
160 by monitoring the weight loss. The initial weight of SF composite scaffolds was recorded  
161 under absolute dry conditions. Then the scaffolds were placed in PBS solution on a  
162 thermostatic oscillator at 37 °C. The samples were collected (0, 10, 20, 30, 40, 50 and 60  
163 days), dried at 55 °C, and weighed to calculate weight loss.

#### 164 **2.4 Cell proliferation on SF electrospun membranes**

165 Prior to cell culture, SF membranes were placed on glass coverslips ( $\Phi$  14 mm),  
166 sterilized with 75% ethanol for 30 min, and then soaked overnight in culture medium  
167 (Gibco). To test the biocompatibility of the membranes, BMSCs and EPCs were co-  
168 cultured at the ratio of 1:0, 0:1, 2:1, 1:1 and 1:2 at a density of  $10^4$  cells (BMSCs +  
169 EPCs)/cm<sup>2</sup>. Cells were cocultured in a 1:1 mixture of  $\alpha$ -MEM medium (Gibco) and  
170 endothelial growth medium-2 (EGM-2, Lonza Inc) at 37 °C in 5% CO<sub>2</sub>. Cell proliferation  
171 was assessed using the cell counting kit-8 reagent (CCK-8, Beyotime, Haimen, China) on  
172 days 1, 3, and 5.

173 BMSCs and EPCs were labeled with Dil (green, Beyotime) and Dio (red, Beyotime)  
174 dyes, respectively. Labeled cells were seeded on the membranes at the ratios described  
175 above. On days 1, 3, and 5 of the incubation period the cells were observed with a  
176 fluorescence microscope (Carl Zeiss Inc, Thornwood, NY, USA). Cell morphology was  
177 also observed by SEM.

#### 178 **2.5 Evaluation of *in vitro* osteogenesis**

##### 179 **2.5.1 ALP and AR staining**



180 The BMSCs and EPCs were seeded on membranes as described above and co-  
181 cultured at the ratio of 1:0, 2:1, 1:1 and 1:2. Cell culture of 1:0, 2:1, 1:1 and 1:2 groups  
182 was carried out in 1:1 mixture of osteogenic differentiation medium (supplemented with  
183 10% FBS, 1% penicillin/streptomycin, 0.1  $\mu\text{mol/L}$  dexamethasone, 10  $\text{mmol/L}$   $\beta$ -glycerol  
184 phosphate, and 50  $\mu\text{mol/L}$  ascorbate) and endothelial growth medium-2 at 37 °C in 5%  
185  $\text{CO}_2$ . In control group, BMSCs were cultured with  $\alpha$ -MEM medium containing 10 % fetal  
186 bovine serum and 1 % penicillin-streptomycin.

187 After osteogenic induction for 7 days, cells were stained with an alkaline  
188 phosphatase (ALP) staining kit (Cyagen, Guangzhou, China). Images of ALP staining  
189 were captured using an optical microscope (Zeiss). On day 14 of osteogenic induction,  
190 the recommended amount of pre-prepared 0.1% alizarin red (AR) staining solution  
191 (Cyagen, Guangzhou, China) was added and incubated for 20 min. After three washes in  
192 PBS, images of the red-stained calcareous nodules were taken using an optical  
193 microscope (Zeiss).

#### 194 **2.5.2 qRT-PCR**

195 At 7 days and 14 days of osteogenic induction, quantitative real-time polymerase  
196 chain reaction (qRT-PCR) was performed to detect the expression of the osteogenic genes  
197 *COL1A1*, *ALPL*, *RUNX2*, and *BGLAP*. Total RNA was extracted using RNA isolater Total  
198 RNA Extraction Reagent (Vazyme Biotech Co.,Ltd, Jiangsu, China) and complementary  
199 DNA (cDNA) was synthesized using the cDNA kit (Thermo Fisher Scientific). PCR  
200 amplification was performed in a CFX96 <sup>TM</sup> Real-Time PCR System instrument using

201 the iTap™ Universal SYBR Green Supermix. Relative expression of target genes was  
202 calculated as follows:  $\chi=2^{-\Delta\Delta CT}$ . The primer sequences are listed in Table 1.

### 203 **2.5.3 Western blot**

204 Radio immunoprecipitation assay lysis buffer (RIPA, Beyotime) containing protease  
205 inhibitors was used to extract cellular proteins. The protein concentration was determined  
206 using a BCA kit (Absin Bioscience Inc., abs9232 Shanghai, China). After blocking for 1  
207 h, the membranes were incubated overnight at 4 °C with the desired antibodies (Abcam,  
208 anti-collagen I: ab34710, anti-osteocalcin: ab93876, anti- $\alpha$ -Tubulin: ab7291, anti-ALP:  
209 ab229126, anti-RUNX2: ab192256, anti-VEGF: ab46154). The following day the  
210 membranes were incubated with horseradish peroxidase (HRP) labeled secondary  
211 antibodies (ab6721 or ab6788) for 1 h. The hypersensitive chemiluminescence substrate  
212 (Beyotime) was added to the membrane for visualization. The optical density (OD) value  
213 was analyzed by ImageJ software (National Institutes of Health, USA) with  $\alpha$ -Tubulin  
214 serving as control for the standardization of protein content.

### 215 **2.5.4 Immunofluorescence**

216 After 7 and 14 days of osteogenic induction, the cells were fixed and immersed in  
217 blocking buffer. The cell membranes were permeabilized by 0.1% Triton X-100 for 10  
218 min and the cells were incubated in the desired diluted antibodies (anti-collagen I,  
219 ab34710, anti-CD31, ab28364) for 8 h at 4 °C. Then the cells were incubated with an  
220 Alexa Fluor conjugated secondary antibody (ab150075) mixed with phalloidin (C1033,

221 Beyotime) for 1 h. Nuclei were counterstained using 4',6-diamidino-2-phenylindole  
222 (DAPI, Beyotime). Images were captured using a fluorescence microscope.

## 223 **2.6 Evaluation of *in vitro* angiogenesis by the co-cultured cells**

224 The BMSCs and EPCs were seeded on the membranes as described above and co-  
225 cultured at the ratio of 1:0, 2:1, 1:1 and 1:2. Cell culture of 1:0, 2:1, 1:1 and 1:2 groups  
226 was carried out in 1:1 mixture of endothelial growth medium-2 (supplemented with 2%  
227 FBS and growth factors, including 50 ng/ml VEGF, 1 ng/ml basic fibroblast growth factor  
228 and 2 ng/ml insulin-like growth factor 1) and  $\alpha$ -MEM medium at 37 °C in 5% CO<sub>2</sub>. In  
229 control group, BMSCs were cultured with  $\alpha$ -MEM medium containing 10 % fetal bovine  
230 serum and 1 % penicillin-streptomycin.

231 At 3 and 5 days of culture, qRT-PCR and Western blot analysis were performed to  
232 detect the expression of vascular endothelial growth factor (VEGF). The expression of  
233 CD31, a vascular marker protein, was detected by immunofluorescence. The  
234 experimental steps were performed as described in section 2.4 above. The genes and  
235 corresponding primers are listed in Table 1.

## 236 **2.7 Animal studies**

237 BMSCs and EPCs (1:1) were co-cultured on electrospun SF membranes for 7 days  
238 to form a biomimetic periosteum. On the 7<sup>th</sup> day the cell-laden membranes were wrapped  
239 around the SF tubular scaffolds to form the biomimetic periosteum-diaphysis substitutes  
240 for the subsequent animal experiments. Biomimetic periosteum-diaphysis substitutes  
241 without cells were also prepared for the control.

242 New Zealand white rabbits (6 weeks) were used in the animal experiments. All  
243 surgical procedures were approved by the Soochow University Laboratory Animal  
244 Management Committee. All *in vivo* animal experiments were performed according to  
245 previously described experimental protocols [25-27, 38]. Feeding and drinking water  
246 were prohibited 12 hours before surgery. The rabbits were anesthetized with 4%  
247 isoflurane and 30% oxygen. The rabbit was placed in a lateral position, and the left upper  
248 limb was prepared with skin and sterile drapes. First, the operative limb was wrapped  
249 with a tourniquet and a 4 cm longitudinal incision was made in the posterior middle of  
250 the forearm. The skin, fascia and muscle were cut open in turn until the exposure the  
251 radius. A critical-size bone defect model was prepared by removing a 15 mm bone block  
252 using a miniature chainsaw. Twenty-four rabbits were randomly divided into four groups.  
253 The rabbits in the control group had bilateral radius defects without implants. In the SF  
254 group, tubular SF scaffolds were implanted into the defects. In the SFM group, the defects  
255 were implanted with cell-free periosteum-bone substitutes. Finally, animals in the SFMC  
256 group received the implantation of cell-laden periosteum-bone substitutes. The fascia and  
257 skin were sutured, and the wound was bandaged. Feeding and drinking were resumed 6  
258 hours after operation, and the rabbits were kept in separate cages. Intramuscular penicillin  
259 (5 mg/kg) was performed for 3 days after operation to prevent infection.

## 260 **2.8 Micro-CT**

261 Rabbits were euthanized at 6 or 12 weeks. Radius specimens were harvested for  
262 gross observation and fixed with 10% formalin (Aladdin). All samples were scanned

263 using a Micro-CT (SkyScan, Aartselaar, Belgium). Data reconstruction was performed  
264 using NRecon software (Skyscan) to generate 2D and 3D images. Image analysis was  
265 performed using the CTAn software (Skyscan). The volume of interest in bone  
266 regeneration was defined as the cylindrical area covering the initial bone defect and the  
267 bone volume to tissue volume ratio (BV/ TV, %) was calculated.

## 268 **2.9 Histology and immunohistochemistry**

269 The samples were decalcified in 14% ethylene diamine tetraacetic acid (EDTA,  
270 Aladdin) for 2 months. After the decalcification was complete, the bones were paraffin  
271 embedded, sectioned, deparaffinized with xylene for 20 min, and dehydrated in alcohol  
272 for 10 min. For histologic observations, sections were stained with hematoxylin and eosin  
273 (H&E). For immunohistochemical staining, sections were blocked with 1% bovine serum  
274 albumin (Aladdin) after an incubation in 2 mg/mL hyaluronidase (Aladdin). The sections  
275 were incubated with an anti-COL I (Abcam, ab34710) or anti-CD31 (Abcam, ab28364)  
276 antibody overnight at 4 °C. Subsequently, the sections were incubated with HRP-  
277 conjugated goat anti-rabbit secondary antibody (Abcam, ab6721) and visualized using  
278 3,3'-diaminobenzidine solution (Vector Laboratories, Germany). The percentage of  
279 positive cells was quantitatively evaluated using ImageJ software.

## 280 **2.10 Statistical analysis**

281 The experimental results were statistically analyzed using the SPSS 19.0 and Sigma  
282 Plot 14.0 software packages. Results were expressed as mean  $\pm$  standard deviation.  
283 Comparisons between two groups were performed with independent two-tailed Student's

284 *t*-test while comparisons between multiple groups were conducted using one-way  
285 Analysis of Variance (ANOVA) followed by Tukey's post hoc test. A *p* value of less than  
286 0.05 was considered statistically significant.

287

### 288 **3. Results**

#### 289 **3.1 The structure of biomimetic periosteum-diaphysis substitutes**

290 The biomimetic periosteum-diaphysis substitute was composed of an electrospun SF  
291 membrane and a tubular SF scaffold, as shown in Figure 1A, B, C, F. The electrospun  
292 membrane acted as the biomimetic periosteum. The surface morphology of these  
293 membranes was observed via SEM. The average fiber diameter was  $0.6 \pm 0.13 \mu\text{m}$  (Figure  
294 S1). Water contact angle of the membrane was  $42.0 \pm 1.2^\circ$  (Figure 1D), indicating that  
295 the substrate was hydrophilic, which is beneficial for cell growth and nutrient transport.  
296 The stress–strain curve of electrospun SF membranes (Figure 1E) showed that the  
297 membrane was elastic, and its tensile strength and maximum strain were 1.5 MPa and  
298 15%, respectively.

299 To support the artificial periosteum and promote bone regeneration, an SF tubular  
300 scaffold with directionally connected pores was utilized as biomimetic diaphysis (Figure  
301 1F). The pores of these tubular scaffolds were oriented with pore diameters ranging from  
302 20 to 100  $\mu\text{m}$  and a porosity of approximately 60%. It was reported that the minimum  
303 pore size necessary for significant bone growth was 75-100  $\mu\text{m}$  [28], while the micropores  
304 could facilitate the exchange of nutrients, oxygen, and the transport of waste.

305 Subsequently, electrospun SF membranes were wrapped on the surface of SF tubular  
306 scaffolds to form combined periosteum-bone substitute. Obtained SEM images clearly  
307 showed the membrane layer and the hollow scaffold structure. Photographs of the scaffold  
308 further illustrated the tubular structure (Figure 1G). *In vitro* degradation assays showed  
309 that 40% of SF was partially degraded within 2 months (Figure 1H).

### 310 **3.2 *In vitro* biocompatibility of electrospun SF membranes**

311 To evaluate the effect of electrospun SF membranes on the proliferation of co-  
312 cultured cells, BMSCs and EPCs were seeded on the membranes for 1, 3 and 5 days at  
313 different ratios (1:0, 0:1, 2:1, 1:1 and 1:2). Cell proliferation assays were performed using  
314 cell tracking (Figure 2A) and the CCK-8 cell proliferation assay (Figure 2C). The results  
315 showed that both BMSCs (green) and EPCs (red) grew well on the membranes. The  
316 number of both cells increased significantly, and there was no significant difference  
317 between the proliferation of the two different cell populations (Figure 2A, C). The  
318 morphology of cells on the SF membranes was also determined by SEM. As shown in  
319 Figure 2B, cells spread well on the nanofibers at 3 days. These results indicated the  
320 excellent biocompatibility of electrospun SF membranes that were able to support the  
321 proliferation of co-cultured cells.

### 322 **3.3 *In vitro* osteogenesis by co-cultured cells on electrospun SF membranes**

323 To evaluate the osteogenic potential of co-cultured BMSCs and EPCs on electrospun  
324 SF membranes, the cells were stained to detect the expression of ALP. The expression of  
325 genes and proteins involved in osteogenic differentiation was quantitated, and the

326 deposition of calcium crystals was also visualized. The results showed that the expression  
327 of ALP in co-cultured cells (2: 1, 1: 1, 1: 2) was much higher compared to monoculture.  
328 The expression of ALP at a 1:1 BMSC to EPC ratio was significantly up-regulated (Figure  
329 3A, C). AR staining showed abundant calcium deposits after 14 d in culture at 1:1 cell  
330 ratio. Calcium nodules were also seen in other co-culture groups but their intensity was  
331 lower (Figure 3B, D). The results of qRT-PCR and Western blot analyses showed that the  
332 expression of osteogenic gene transcripts (*ALPL*, *RUNX2*, *COL1A1*, *BGLAP*) and  
333 proteins (ALP, Runx2, COL I, and OCN) were significantly upregulated at 1:1 cell ratio  
334 (Figure 4). In addition, immunofluorescence images clearly demonstrated the expression  
335 of collagen I (COL I). These results demonstrated that the co-culture of BMSCs and EPCs  
336 at a ratio of 1:1 provided optimal conditions to induce osteogenic differentiation of stem  
337 cells (Figure 5). In summary, we found that the co-culture of BMSCs and EPCs could  
338 promote the osteogenic differentiation of BMSCs, and the optimal BMSC to EPC ratio  
339 was 1:1.

#### 340 **3.4 *In vitro* angiogenesis ability of BMSCs and EPCs co-cultured on the electrospun** 341 **SF membranes**

342 VEGF and CD31 are markers of early angiogenesis, the *in vitro* expression of VEGF  
343 and CD31 was detected at different time points, such as 3, 4, 5, 6 and 7 days [29-32]. In  
344 this experiment, we intended to evaluate angiogenesis in early time, and then *in vitro*  
345 expression of VEGF and CD31 at 3 and 5 days was detected. The results showed the  
346 upregulated expression of angiogenic genes and proteins in co-cultured cells at a ratio of



347 2:1, 1:1 and 1:2. The results of qRT-PCR and Western blot showed that VEGF was  
348 significantly upregulated both at mRNA and protein level in co-cultures at 1:2 cell ratio,  
349 followed by the 1:1 group, the 2:1 group, the 1:0 group and the Control group (Figure 6).  
350 The expression of CD31 was detected visually by immunofluorescence (Figure 7). The  
351 immunofluorescent staining showed that culturing cells at a 1:2 ratio resulted in the most  
352 pronounced CD31 expression, followed by the 1:1 group, the 2:1 group, the 1:0 group  
353 and the Control group. These results suggested that that culturing BMSCs and EPCs at a  
354 ratio of 1:2 resulted in more *in vitro* angiogenic changes, followed by the 1:1, 2:1, 1:0,  
355 and the Control group.

### 356 **3.5 Repair of segmental bone defects in rabbit radius using the biomimetic** 357 **periosteum-diaphysis substitutes**

358 Cell-laden periosteum-diaphysis substitutes were used to repair large segmental bone  
359 defects in the radius of rabbits. To prepare the cell-loaded periosteum-diaphysis  
360 substitutes, BMSCs and EPCs were incubated at a ratio of 1:1 on electrospun SF  
361 membranes for 7 days. The implantation of the biomimetic bone grafts was carried out as  
362 described in section 2.6. The samples were harvested at 6 and 12 weeks after surgery. On  
363 gross visual inspection, only a small amount of new bone formed in the control group at  
364 6 weeks (Figure 8A). In comparison, the groups implanted with various forms of bone  
365 substitutes exhibited better healing tendencies, with animals in the SFMC group showing  
366 the most extensive repair. After 12 weeks, the bone defects in the control group were still  
367 clearly obvious, while the defects were almost completely filled with new bone in animals

368 receiving implanted scaffolds. Consistently, the SFMC group showed the best healing  
369 results by gross observation.

370 The quality of the newly formed bone was analyzed by micro-CT (Figure 8B). In  
371 control animals, the bone defects were still apparent at 6 weeks after the initial bone loss.  
372 Newly formed bone was evident in the SF, SFM, and SFMC groups, connecting the  
373 proximal and distal ends of the radius defect. Interestingly, the formation of medullary  
374 cavity-like structures was already visible at this time point in the SFMC group.  
375 Regenerating bones in the other groups did not show this feature. In addition, the SFMC  
376 group showed more new bone formation than other groups. However, the morphology of  
377 the new bone remained significantly different from that of a non-injured radius. At 12  
378 weeks, the bone volume to tissue volume ratio (BV/TV) doubled (Figure 8C). The best  
379 bone repair was seen in the SFMC group where BV/TV reached more than 70%. These  
380 observations clearly indicated that superior bone healing in animals receiving cell-laden  
381 SF-based biomimetic periosteum-diaphysis substitutes. In this group, segmental bone  
382 defects healed significantly better and medullary cavities were formed, to mimick the  
383 natural structure of long bone.

384 Sections of newly formed bone segments were also observed microscopically using  
385 H&E staining (Figure 9A, C). As expected, there was very little evidence of bone repair  
386 in the control group at 6 weeks. In contrast, in the SF, SFM, and SFMC groups a  
387 significant amount of new bone matrix was visible in the area of the initial defect. New  
388 bone formation increased significantly by 12 weeks. Again, noticeably less bone

389 formation was evident in the control group. In contrast, in the SFMC group, a clear bone  
390 marrow cavity formed and myeloid tissue started to enter into this space. These results  
391 underline the fact that large segmental bone defects have a very limited capacity to heal  
392 spontaneously. The amount of new bone increased in the SF group but the new bone was  
393 growing into the inserted grafts from the two ends towards the middle. These results  
394 indicated that the oriented tubular SF scaffolds could connect the broken ends and  
395 promoted nutrient circulation, resulting in some repair. Bone regeneration and remodeling  
396 was much faster and efficient in the SFMC group, where the forming new bone showed  
397 some remarkable similarity to normal bone. These findings clearly supported that  
398 importance of the BMSCs and EPCs in promoting osteogenesis. In summary, these results  
399 showed that the biomimetic periosteum-diaphysis substitute formed by the culturing of  
400 BMSCs and EPCs onto electrospun SF membranes combined with a degradable SF  
401 tubular scaffold demonstrated a remarkable potential to promote the repair of large  
402 segmental bone defects.

403 The expression of osteogenic markers was also investigated in the freshly formed  
404 bone segments using immunohistochemistry (Figure 9B, D). The expression of COL I  
405 increased in all groups at 6 and 12 weeks after implantation, with the highest expression  
406 levels in the SFMC group. In conclusion, the results showed that the biomimetic  
407 periosteum-diaphysis substitute could promote the expression of bone-related matrix  
408 proteins, with the amount of expression increasing during longer implantation times. Thus,

409 the biomimetic periosteum-diaphysis substitute had the potential to promote osteogenesis  
410 and the repair of large segmental bone defects.

411

#### 412 **4. Discussion**

413 The periosteum, a fibrous tissue covering the surface of all bones, is the natural  
414 source of pluripotent progenitor cells that mediate the repair of fractured bones [33]. In  
415 1739, Duhamel noted that the function of the deep layer of the periosteum was similar to  
416 that of the cambium layer of trees and named it accordingly [34]. The periosteum consists  
417 of two distinct layers. The outer fibrous layer is mainly composed of fibroblasts  
418 embedded in collagen fibers. In contrast, the inner cambium layer is the source of cells  
419 and growth factors necessary for bone repair. In addition, the periosteum also contains a  
420 network of arteries and veins forming a dense reticular vascular layer around bones.  
421 During the process of bone regeneration, the cambium layer provides a variety of stem  
422 cells, cytokines, and growth factors. The characteristic of cambium layer composition is  
423 vital for bone regeneration, and it can accelerate bone formation by promoting  
424 endochondral and intramembranous ossification [35, 36]. Several studies have shown that  
425 the lack of periosteum resulted in the nonunion or malunion, while autologous periosteum  
426 transplantation could promote bone healing [37].

427 Given the indispensable role of periosteum, extensive attempts have been made to  
428 create tissue-engineered substitutes to facilitate the regeneration of injured bone tissue.  
429 While early work focused primarily on providing a replacement for the physical structures  
430 of the periosteum, more advanced biomimetic periosteum, containing cellular  
431 components, showed clear advantages by supporting osteogenesis and angiogenesis.

432 These biomimetic grafts were comparable to the native periosteum both in cellular  
433 composition and function. However, the application of cell-based biomimetic periosteum  
434 is limited by unsatisfactory tensile properties and restrictive storage requirements [38].  
435 Artificial periosteum transplanted into bone defects is exposed to forces created by the  
436 movements of fractured bone ends. Once the artificial periosteum is broken, the benefits  
437 become limited.

438 In this study, we prepared a biomimetic periosteum replicating the key features of  
439 the natural cambium layer. To achieve this, BMSCs and EPCs were seeded onto  
440 electrospun SF membranes. This approach improved the mechanical properties of the  
441 artificial mimics, while recreating the microstructure of natural periosteum. Natural ECM  
442 provides a surface for cellular growth and enhances cell differentiation and maturation .  
443 SF has good biocompatibility and low immunogenicity [39]. Furthermore, compared with  
444 collagen, SF membranes had better mechanical properties and longer degradation time.  
445 Low-cost production and ease of use make SF an ideal biomaterial for the preparation of  
446 biomimetic periosteum. Previous studies used various polymers, including polylactic acid  
447 and polycaprolactone to replace the ECM [40]. Although these polymers possessed  
448 satisfying mechanical properties, the drugs and/or growth factors needed to be  
449 encapsulated in them to improve their biological characteristics. Often these molecules  
450 had burst release in the early stage, causing anomalous cell behavior and unpredictable  
451 side effects. In addition, in these versions of artificial periosteum, endogenous scaffolds  
452 were limited to the use of cell-sheets and acellular scaffolds due to issues with  
453 biocompatibility and immunogenicity [41]. However, the use of such scaffolds was found  
454 to be limited by unsatisfactory mechanical properties and rapid degradation. In our study,  
455 we combined the advantages of artificial polymer membranes and endogenous scaffolds

456 by seeding BMSCs and EPCs onto an SF membrane. The created biomimetic periosteum,  
457 assembled on an electrospun SF membrane, retained the advantages of natural ECM, had  
458 excellent mechanical properties, and a slow degradation rate. Moreover, we achieved the  
459 long-term release of osteogenic and angiogenic growth factors by loading BMSCs and  
460 EPCs onto the membrane. The use of electrospun SF membranes loaded with BMSCs  
461 and EPCs appears to be a promising strategy for the development of a biomimetic  
462 periosteum.

463 The process of bone remodeling includes the differentiation of BMSCs, and  
464 angiogenesis induced by EPCs. BMSCs that are indispensable stem cells in the formation  
465 and differentiation of osteoblast at the implant-bone interface. BMSCs transplanted into  
466 bone defects promoted bone regeneration through proliferation, migration, osteogenic  
467 differentiation, and calcium deposition. In addition, BMSCs can also contribute to  
468 accelerated angiogenesis by endogenous EPCs through paracrine secretory pathways [42].  
469 Through this mechanism they secrete proangiogenic cytokines, such as VEGF-A, thus  
470 promoting the differentiation and homing of EPCs, and the repair of injured endothelial  
471 cells [43]. The recruitment of EPCs has been shown to significantly promote  
472 neovascularization [44]. Many studies have found that BMSC and EPC interact by  
473 secreting various growth factors such as VEGF and platelet derived growth factor (PDGF)  
474 [45]. BMSC could also reduce EPC apoptosis through direct cell-cell contact. Liang et al.  
475 found that co-culture of BMSC and EPC enhanced PDGF secretion and angiogenesis [46].  
476 Aguirre et al. reported that BMSCs and EPCs jointly promote the formation of tubular  
477 structures in a co-culture system [47]. Differentiating EPCs also secrete BMP-2, one of  
478 the most powerful osteogenesis-promoting cytokines. BMPs accelerate osteogenesis and  
479 angiogenesis simultaneously, while reducing the occurrence of complications during

480 bone remodeling [48]. Furthermore, it was reported that directional mitochondrial  
481 exchange occurred between MSCs and vascular endothelial cells via intercellular  
482 tunneling nanotubes (TNT) [49]. This TNT-mediated mitochondrial transfer has the  
483 potential to protect injured vascular endothelial cells from mitochondrial dysfunction, by  
484 increasing mitochondrial membrane potential, inhibiting the excessive accumulation of  
485 reactive oxygen species, and the reconstitution of mitochondrial respiration [50].

486 Previous studies have shown that the co-culture of BMSCs and EPCs can promote  
487 osteogenesis and angiogenesis. He et al. reported that the optimal ratio of BMSCs and  
488 EPCs in osteogenic differentiation was 1:1, with the highest ALP activity occurring at this  
489 ratio [51]. In contrast, Peng et al. found that the optimal BMSC to EPC ratio for  
490 angiogenesis and osteogenesis was 1:3 and 2:1, respectively [52]. Fu et al. also studied  
491 the behavior of EPCs and BMSCs in co-cultures [53]. They found that increasing the  
492 proportion of EPCs promoted the expression of CD31 and improved the vascularization  
493 of scaffolds. The expression of osteogenic and angiogenic markers was the highest when  
494 the EPC to BMSC ratio was 3:1. In our study, co-culturing BMSCs and EPCs at a ratio  
495 of 1:1 showed the most effective in both osteogenesis and angiogenesis. Therefore, we  
496 used BMSCs and EPCs at this ratio to prepare biomimetic periosteum to replicate the  
497 ability of natural cambium layer to promote bone regeneration.

498 Nonunion is a potentially catastrophic complication of long segmental bone fractures.  
499 Ensuring adequate mechanical support is a critical requirement in the treatment of these  
500 defects. To achieve this aim, we designed a hollow tubular scaffold with oriented  
501 connected pores mimicking the porous structure and oriented collagen fibers of native  
502 long bones. Studies have shown that compared to randomly porous scaffolds, alternatives  
503 with directional porous structure were more conducive to the migration of cells, the

504 exchange of nutrients and the deposition of ECM [54]. Currently, 3D printing and  
505 directional freeze-drying represent the most promising technologies to prepare  
506 directionally porous scaffolds. However, 3D printing is not suitable for water-soluble  
507 materials while freeze-drying shows superior versatility and cost. Therefore, we utilized  
508 directional freeze-drying to prepare hollow tubular scaffolds containing oriented and  
509 connected pores to fill the space between the ends of broken bones. The connected pores  
510 in these structures facilitate the migration and deposition of osteoblasts in the bone matrix  
511 [55]. The importance of anatomic reduction and stable fixation in the healing of bone  
512 fractures has long been recognized [56]. Hollow tubular scaffolds can provide mechanical  
513 support, helping to fix the long axis of the broken ends along natural force lines. It is  
514 important to note that the implantation of scaffolds can prevent soft tissues from  
515 occupying bone defects [57], thus reducing the risk of bone nonunion. Therefore, the  
516 combination of hollow tubular scaffolds with biomimetic periosteum represents an ideal  
517 combination in promoting bone regeneration.

518         Various studies have reported the application of biomimetic periosteal substitutes.  
519 For example, some studies have combined artificial periosteum and allogeneic bone to  
520 form periosteal bone substitute, but the defect of allogeneic bone graft is inevitable [58,  
521 59]. In addition, there are some studies combined artificial periosteum and artificial bone  
522 scaffold [38], but these scaffolds have no directional pores and interconnected pores,  
523 which is not conducive to the transport of nutrients, air and metabolic waste. Our  
524 approach differs in three respects. First, we offset the disadvantages of the poor  
525 mechanical properties of ECM sheets by seeding cells on easily prepared and strong SF  
526 membranes. Second, we verified that the optimal ratio of BMSCs and EPCs was 1:1. The  
527 SF membranes loaded with the combination of stem cells could act as a source of



528 bioactive factors over a longer period of time, promoting angiogenesis and bone  
529 regeneration. Finally, instead of using a biomimetic periosteum alone, hollow tubular  
530 scaffolds were introduced as a support and space holder. The resulting biomimetic  
531 periosteum-diaphysis substitutes act as an artificial diaphysis in promoting the  
532 regeneration of critical-sized segmental bone defects. The observed medullary cavity  
533 formation in the SFMC treatment group suggests that this approach represents a  
534 promising novel method for supporting bone regeneration.

535

## 536 **5. Conclusion**

537 We developed a biomimetic periosteum-diaphysis substitute by integrating the  
538 biomimetic cambium layer, fabricated by seeding BMSCs and EPCs on an electrospun  
539 SF membrane, with a tubular SF scaffold. The biomimetic periosteum had an ECM-like  
540 microstructure, supporting the proliferation of BMSCs and EPCs and promoting  
541 osteogenesis and angiogenesis. We found that in the construction of biomimetic  
542 periosteum, the optimal ratio of BMSCs and EPCs was 1:1. The SF hollow tubular  
543 scaffold, which acts as biomimetic diaphysis substitute, contains oriented interconnected  
544 pores. Finally, animal experiments demonstrated that the biomimetic periosteum-  
545 diaphysis graft was extremely effective in promoting bone regeneration. Furthermore, the  
546 formation of connected medullary cavities inside these scaffolds even promoted the return  
547 of bone marrow-like cellular composition. These findings clearly demonstrated that the  
548 developed biomimetic periosteum-diaphysis substitute represents a promising approach

549 for the repair of large segmental bone defects, paving the way to provide a novel strategy  
550 for the replacement of large missing bone segments.

551

552 **Author statement**

553 Lili Yu: Conceptualization, Methodology, Validation, Formal analysis, Investigation,  
554 Data curation, Writing - original draft, Writing - review & editing, Visualization. Qiang  
555 Wei: Validation, Formal analysis, Investigation, Writing - review & editing. Jiaying Li:  
556 Methodology, Formal analysis, Writing - review & editing. Huan Wang: Methodology,  
557 Formal analysis, Data curation. Qingchen Meng: Investigation, Data curation. En Xie:  
558 Investigation, Data curation. Zexi Li: Methodology, Formal analysis. Kexin Li:  
559 Methodology. Wenmiao Will Shu: Methodology, Writing - review & editing. Junxi Wu:  
560 Methodology. Lei Yang: Methodology. Yan Cai: Conceptualization, Methodology,  
561 Writing - review & editing. Fengxuan Han: Conceptualization, Formal analysis, Funding  
562 acquisition, Writing - review & editing. Bin Li: Conceptualization, Writing - review &  
563 editing, Visualization, Supervision, Project administration, Funding acquisition.

564

565 **Data and materials availability**

566 All data are available in the main text.

567

568 **Declaration of competing interest**

569 The authors declare that they have no known competing financial interests or  
570 personal relationships that could have appeared to influence the work reported in this  
571 paper.

572

### 573 **Acknowledgments**

574 The authors are grateful for the funding provided for this study by the National Key  
575 Research and Development Program of China (2020YFC1107401), the National Natural  
576 Science Foundation of China (81925027, 82111530157, 31872748), the Royal Society  
577 (IEC\NSFC\201166), Jiangsu Provincial Special Program of Medical Science  
578 (BL2012004), and the Priority Academic Program Development (PAPD) of Jiangsu  
579 Higher Education Institutions.

580

### 581 **References**


- 582 [1] Witek L, Alifarag AM, Tovar N, Lopez CD, Cronstein BN, Rodriguez ED, et al.  
583 Repair of critical-sized long bone defects using dipyridamole-augmented 3D-printed  
584 bioactive ceramic scaffolds. *J Orthop Res* 2019; 37: 2499-2507.
- 585 [2] Bornert F, Clauss F, Hua GQ, Idoux-Gillet Y, Keller L, De Grado GF, et al.  
586 Mechanistic illustration: How newly-formed blood vessels stopped by the mineral  
587 blocks of bone substitutes can be avoided by using innovative combined therapeutics.  
588 *Biomedicines* 2021; 9: 952.
- 589 [3] Wu L, Gu Y, Liu L, Tang J, Mao J, Xi K, et al. Hierarchical micro/nanofibrous  
590 membranes of sustained releasing VEGF for periosteal regeneration. *Biomaterials*  
591 2020; 227: 119555.
- 592 [4] Wieding J, Lindner T, Bergschmidt P, Bader R. Biomechanical stability of novel  
593 mechanically adapted open-porous titanium scaffolds in metatarsal bone defects of  
594 sheep. *Biomaterials* 2015; 46: 35-47.
- 595 [5] Zhang M, Matinlinna J, Tsoi J, Liu W, Cui X, Lu W, et al. Recent developments in  
596 biomaterials for long-bone segmental defect reconstruction: A narrative overview. *J*  
597 *Orthop Transl* 2020; 22: 26-33.
- 598 [6] Zhou Y, Han S, Xiao L, Han P, Wang S, He J, et al. Accelerated host angiogenesis  
599 and immune responses by ion release from mesoporous bioactive glass. *J Mater*  
600 *Chem B* 2018; 6: 3274-3284.

- 601 [7] Zhang X, Awad H, O'Keefe R, Guldberg R, Schwarz E. A perspective: engineering  
602 periosteum for structural bone graft healing. *Clin Orthop Relat R* 2008; 466: 1777-  
603 1787.
- 604 [8] Sun YG, Gao ZW, Zhang XP, Xu ZY, Zhang YH, He BB, et al. 3D-printed, bi-layer,  
605 biomimetic artificial periosteum for boosting bone regeneration. *Bio-Des Manuf*  
606 2022; 5: 540-555.
- 607 [9] Cao S, Zhao Y, Hu Y, Zou L, Chen J. New perspectives: In-situ tissue engineering for  
608 bone repair scaffold. *Compos B Eng* 2020; 202: 108445.
- 609 [10] Kang F, Yi Q, Gu P, Dong Y, Zhang Z, Zhang L, Bai Y. Controlled growth factor  
610 delivery system with osteogenic-angiogenic coupling effect for bone regeneration. *J*  
611 *Orthop Translat* 2021; 31: 110-125.
- 612 [11] Cheng WX, Liu YZ, Meng XB, Zheng ZT, Li LL, Ke LQ, et al. PLGA/ $\beta$ -TCP  
613 composite scaffold incorporating cucurbitacin B promotes bone regeneration by  
614 inducing angiogenesis. *J Orthop Translat* 2021; 31: 41-51.
- 615 [12] Yang Z, Yang Z, Ding L, Zhang P, Liu C, Chen D, et al. Self-adhesive hydrogel  
616 biomimetic periosteum to promote critical-size bone defect repair via synergistic  
617 osteogenesis and angiogenesis. *ACS Appl Mater Inter* 2022; 14: 36395-36410.
- 618 [13] Weisbrod L, Arnold P, Leever J. Radiographic and CT evaluation of recombinant  
619 human bone morphogenetic protein-2-assisted cervical spinal interbody fusion. *Clin*  
620 *Spine Surg* 2019; 32: 71-79.
- 621 [14] Feng Q, Xu J, Zhang K, Yao H, Zheng N, Zheng L, et al. Dynamic and cell-  
622 infiltratable hydrogels as injectable carrier of therapeutic cells and drugs for treating  
623 challenging bone defects. *ACS Cent Sci* 2019; 5: 440-450.
- 624 [15] Li Z, Wang H, Zhang K, Yang B, Xie X, Yang Z, et al. Bisphosphonate-based  
625 hydrogel mediates biomimetic negative feedback regulation of osteoclastic activity  
626 to promote bone regeneration. *Bioact Mater* 2021; 13: 9-22.
- 627 [16] Chen L, Li L, Xing F, Peng J, Peng K, Wang Y, et al. Human urine-derived stem cells:  
628 Potential for cell-based therapy of cartilage defects. *Stem Cells Int* 2018; 2018: 1-14.
- 629 [17] Polymeri A, Giannobile WV, Kaigler D. Bone marrow stromal stem cells in tissue  
630 engineering and regenerative medicine. *Horm Metab Res* 2016; 48: 700-713.
- 631 [18] Lou Y, Wang H, Ye G, Li Y, Liu C, Yu M, Ying B. Periosteal tissue engineering:  
632 current developments and perspectives. *Adv Healthc Mater* 2021; 10: e2100215.
- 633 [19] Kundu B, Rajkhowa R, Kundu SC, Wang X. Silk fibroin biomaterials for tissue  
634 regenerations. *Adv Drug Deliv Rev* 2013; 65: 457-470.
- 635 [20] Yang Y, Xu T, Zhang Q, Piao Y, Bei HP, Zhao X. Biomimetic, stiff, and adhesive  
636 periosteum with osteogenic-angiogenic coupling effect for bone regeneration. *Small*  
637 2021; 17: e2006598.
- 638 [21] Zhu J, Chen D, Du J, Chen X, Wang J, Zhang H, et al. Mechanical matching  
639 nanofibrous vascular scaffold with effective anticoagulation for vascular tissue  
640 engineering. *Compos B Eng* 2020; 186: 107788.
- 641 [22] Wu X, Liu Y, Li X, Wen P, Zhang Y, Long Y, et al. Preparation of aligned porous  
642 gelatin scaffolds by unidirectional freeze-drying method. *Acta Biomater* 2010; 6:  
643 1167-1177.
- 644 [23] Lou Z, Han X, Liu J, Ma Q, Yan H, Yuan C, et al. Nano-Fe<sub>3</sub>O<sub>4</sub>/bamboo  
645 bundles/phenolic resin oriented recombination ternary composite with enhanced  
646 multiple functions. *Compos B Eng* 2021; 226: 109335.

- 647 [24]Jiang SJ, Wang MH, Wang ZY, Gao HL, Chen SM, Cong YH, et al. Radially porous  
648 nanocomposite scaffolds with enhanced capability for guiding bone regeneration in  
649 vivo. *Adv Funct Mater* 2022; 32: 2110931.
- 650 [25]Zhang H, Zhou Y, Yu N, Ma H, Wang K, Liu J, et al. Construction of vascularized  
651 tissue-engineered bone with polylysine-modified coral hydroxyapatite and a double  
652 cell-sheet complex to repair a large radius bone defect in rabbits. *Acta Biomater* 2019;  
653 91: 82-98.
- 654 [26]Zha Y, Li Y, Lin T, Chen J, Zhang S, Wang J. Progenitor cell-derived exosomes  
655 endowed with VEGF plasmids enhance osteogenic induction and vascular  
656 remodeling in large segmental bone defects. *Theranostics* 2021; 11: 397-409.
- 657 [27]Zheng S, Zhong H, Cheng H, Li X, Zeng G, Chen T, et al. Engineering  
658 multifunctional hydrogel with osteogenic capacity for critical-size segmental bone  
659 defect repair. *Front Bioeng Biotechnol* 2022; 10: 899457.
- 660 [28]Murphy CM, Haugh MG, O'Brien FJ. The effect of mean pore size on cell attachment,  
661 proliferation and migration in collagen-glycosaminoglycan scaffolds for bone tissue  
662 engineering. *Biomaterials* 2010; 31: 461-466.
- 663 [29]Yang Z, Yang Z, Ding L, Zhang P, Liu C, Chen D, et al. Self-adhesive hydrogel  
664 biomimetic periosteum to promote critical-size bone defect repair via synergistic  
665 osteogenesis and angiogenesis. *ACS Appl Mater Interfaces* 2022; 14: 36395-36410.
- 666 [30]Parthiban SP, Athirasala A, Tahayeri A, Abdelmoniem R, George A, Bertassoni LE.  
667 BoneMA-synthesis and characterization of a methacrylated bone-derived hydrogel  
668 for bioprinting of in-vitrovascularized tissue constructs. *Biofabrication* 2021; 13:  
669 035031.
- 670 [31]Zhang H, Ma W, Ma H, Qin C, Chen J, Wu C. Spindle-like zinc silicate nanoparticles  
671 accelerating innervated and vascularized skin burn wound healing. *Adv Healthc  
672 Mater* 2022; 11: e2102359.
- 673 [32]Cui J, Yu X, Yu B, Yang X, Fu Z, Wan J, et al. Coaxially fabricated dual-drug loading  
674 electrospinning fibrous mat with programmed releasing behavior to boost  
675 vascularized bone regeneration. *Adv Healthc Mater* 2022; 11: e2200571.
- 676 [33]Lin X, Zhao C, Zhu P, Chen J, Yu H, Cai Y, et al. Periosteum extracellular-matrix-  
677 mediated acellular mineralization during bone formation. *Adv Healthc Mater* 2018;  
678 7: 1700660.
- 679 [34]Bilkay U, Tokat C, Helvacı E, Ozek C, Zekioglu O, Onat T, et al. Osteogenic  
680 capacities of tibial and cranial periosteum: a biochemical and histologic study. *J  
681 Craniofac Surg* 2008; 19: 453-458.
- 682 [35]Zhao L, Zhao JL, Yu JJ, Sun R, Zhang XF, Hu SH. In vivo investigation of tissue-  
683 engineered periosteum for the repair of allogeneic critical size bone defects in rabbits.  
684 *Regen Med* 2017; 12: 353-364.
- 685 [36]Ho-Shui-Ling A, Bolander J, Rustom LE, Johnson AW, Luyten FP, Picart C. Bone  
686 regeneration strategies: Engineered scaffolds, bioactive molecules and stem cells  
687 current stage and future perspectives. *Biomaterials* 2018; 180: 143-162.
- 688 [37]Moore SR, Heu C, Yu NYC, Whan RM, Knothe UR, Milz S, et al. Translating  
689 periosteum's regenerative power: insights from quantitative analysis of tissue genesis  
690 with a periosteum substitute implant. *Stem Cell Transl Med* 2016; 5: 1739-1749.
- 691 [38]Yu Y, Wang Y, Zhang W, Wang H, Li J, Pan L, et al. Biomimetic periosteum-bone  
692 substitute composed of preosteoblast-derived matrix and hydrogel for large  
693 segmental bone defect repair. *Acta Biomater* 2020; 113: 317-327.

- 694 [39] Wang Q, Zhou S, Wang S, You R, Yan S, Zhang Q, et al. Bioactive silk fibroin  
695 scaffold with nanoarchitecture for wound healing. *Compos B Eng* 2021; 224: 109165.
- 696 [40] Han F, Hu Y, Li J, Gong J, Guo Q, Zhu C, et al. In situ silk fibroin-mediated crystal  
697 formation of octacalcium phosphate and its application in bone repair. *Mat Sci Eng*  
698 *C-Mater* 2019; 95: 1-10.
- 699 [41] Wei Q, Wang S, Han F, Wang H, Zhang W, Yu Q, et al. Cellular modulation by the  
700 mechanical cues from biomaterials for tissue engineering. *Biomater Transl* 2021; 2:  
701 323-342.
- 702 [42] Lian M, Sun B, Han Y, Yu B, Xin W, Xu R, et al. A low-temperature-printed  
703 hierarchical porous sponge-like scaffold that promotes cell-material interaction and  
704 modulates paracrine activity of MSCs for vascularized bone regeneration.  
705 *Biomaterials* 2021; 274: 120841.
- 706 [43] Wang Z, Bao X, Hu J, Shen S, Xu G, Wu Y. Nicotinamide riboside enhances  
707 endothelial precursor cell function to promote refractory wound healing through  
708 mediating the Sirt1/AMPK pathway. *Front Pharmacol* 2021; 12: 671563.
- 709 [44] Deng Y, Jiang C, Li C, Li T, Peng M, Wang J, et al. 3D printed scaffolds of calcium  
710 silicate-doped  $\beta$ -TCP synergize with co-cultured endothelial and stromal cells to  
711 promote vascularization and bone formation. *Sci Rep* 2017; 7: 5588.
- 712 [45] Xu H, Wang C, Liu C, Peng Z, Li J, Jin Y, et al. Cotransplantation of mesenchymal  
713 stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis  
714 of the femoral head. *Stem Cells Transl Med* 2021; 10: 781-796.
- 715 [46] Liang T, Zhu L, Gao W, Gong M, Ren J, Yao H, et al. Coculture of endothelial  
716 progenitor cells and mesenchymal stem cells enhanced their proliferation and  
717 angiogenesis through PDGF and Notch signaling. *FEBS Open Bio* 2017; 7: 1722-  
718 1736.
- 719 [47] Khojasteh A, Fahimipour F, Jafarian M, Sharifi D, Jahangir S, Khayyatan F, et al.  
720 Bone engineering in dog mandible: coculturing mesenchymal stem cells with  
721 endothelial progenitor cells in a composite scaffold containing vascular endothelial  
722 growth factor. *J Biomed Mater Res B Appl Biomater* 2017; 105: 1767-1777.
- 723 [48] Fitzpatrick V, Martin-Moldes Z, Deck A, Torres-Sanchez R, Valat A, Cairns D, et al.  
724 Functionalized 3D-printed silk-hydroxyapatite scaffolds for enhanced bone  
725 regeneration with innervation and vascularization. *Biomaterials* 2021; 276: 120995.
- 726 [49] Mittal R, Karhu E, Wang JS, Delgado S, Zukerman R, Mittal J, et al. Cell  
727 communication by tunneling nanotubes: Implications in disease and therapeutic  
728 applications. *J Cell Physiol* 2019; 234: 1130-1146.
- 729 [50] Liu KM, Ji KQ, Guo L, Wu W, Lu HX, Shan PY, et al. Mesenchymal stem cells  
730 rescue injured endothelial cells in an in vitro ischemia-reperfusion model via  
731 tunneling nanotube like structure-mediated mitochondrial transfer. *Microvasc Res*  
732 2014; 92: 10-18.
- 733 [51] He XN, Dziak R, Yuan X, Mao KY, Genco R, Swihart M, et al. BMP2 genetically  
734 engineered MSCs and EPCs promote vascularized bone regeneration in rat critical-  
735 sized calvarial bone defects. *PLoS One* 2013; 8: e60473.
- 736 [52] Peng J, Chen L, Peng K, Chen XW, Wu J, He ZY, et al. Bone marrow mesenchymal  
737 stem cells and endothelial progenitor cells co-culture enhances large segment bone  
738 defect repair. *J Biomed Nanotechnol* 2019; 15: 742-755.
- 739 [53] Fu WL, Xiang Z, Huang FG, Gu ZP, Yu XX, Cen SQ, et al. Coculture of peripheral  
740 blood-derived mesenchymal stem cells and endothelial progenitor cells on strontium-

- 741 doped calcium polyphosphate scaffolds to generate vascularized engineered bone.  
742 *Tissue Eng Pt A* 2015; 21: 948-959.
- 743 [54] Pan Q, Li Y, Xu J, Kang Y, Li Y, Wang B, et al. The effects of tubular structure on  
744 biomaterial aided bone regeneration in distraction osteogenesis. *J Orthop Translat*  
745 2020; 25: 80-86.
- 746 [55] Steijvers E, Ghei A, Xia Z. Manufacturing artificial bone allografts: a perspective.  
747 *Biomater Transl* 2022; 3: 65-80.
- 748 [56] Fuse Y, Zenke Y, Okimoto N, Yoshioka T, Yamanaka Y, Kawasaki M, et al.  
749 Biomechanical comparison of lag screw and non-spiral blade fixation of a novel  
750 femoral trochanteric nail in an osteoporotic bone model. *Sci Rep* 2022; 12: 2045-  
751 2322.
- 752 [57] Yang T, Tamaddon M, Jiang L, Wang J, Liu Z, Liu Z, et al. Bilayered scaffold with  
753 3D printed stiff subchondral bony compartment to provide constant mechanical  
754 support for long-term cartilage regeneration. *J Orthop Translat* 2021; 30: 112-121.
- 755 [58] Li Y, Hoffman MD, Benoit DSW. Matrix metalloproteinase (MMP)-degradable  
756 tissue engineered periosteum coordinates allograft healing via early stage recruitment  
757 and support of host neurovasculature. *Biomaterials* 2021; 268: 120535.
- 758 [59] Romero R, Chubb L, Travers JK, Gonzales TR, Ehrhart NP, Kipper MJ. Coating  
759 cortical bone allografts with periosteum-mimetic scaffolds made of chitosan,  
760 trimethyl chitosan, and heparin. *Carbohydr Polym* 2015; 122: 144-151.
- 761
- 762
- 763
- 764



765

766 **Scheme 1.** Schematic illustration of the preparation and evaluating of a biomimetic

767 periosteum-diaphysis substitute composed of cell-loaded SF nanofibers and an oriented


768 SF scaffold for repair of large segmental bone defect.

769


770



771



772




773 **Figure 1.** Characterizations of the biomimetic periosteum-bone substitute. (A)  
 774 Illustration of structure and preparation of the biomimetic periosteum-bone substitute. (B)  
 775 SEM images of the biomimetic periosteum-bone substitute, in which the electrospun SF  
 776 membrane was wrapped around the SF scaffold. (C) SEM images of the electrospun SF  
 777 membranes. (D) Water contact angle measurements (n=3). (E) Typical stress-strain curve  
 778 of an electrospun SF membrane (n=3). (F) SEM images of the tubular SF scaffold. (G)  
 779 Photographs of the tubular scaffold. (H) Degradation rate of the composite scaffolds (n=3).

780

781


782



783

784 **Figure 2.** Cytocompatibility of electrospun SF membranes. (A) Cell tracking of different  
785 ratios of BMSCs (green) and EPCs (red) co-cultured on electrospun membranes at 1, 3  
786 and 5 days. (B) SEM images of co-cultured BMSCs and EPCs on electrospun membranes  
787 at 3 days. (C) Proliferation of different ratios of co-cultured BMSCs and EPCs on SF  
788 membranes as detected by CCK-8 assays at 1, 3 and 5 days (n=3).

789



790

791 **Figure 3.** *In vitro* osteogenic differentiation of BMSCs and EPCs co-cultured on

792 electrospun SF membranes. (A) Representative images of ALP staining on day 7. (B)

793 Representative images of AR staining showing calcium deposits on day 14. (C)


794 Quantitative analysis of ALP staining and (D) AR staining. \*,  $p < 0.05$ ; ns, no significant

795 difference.  $n=3$ .

796

797


798



799

800 **Figure 4.** Evaluation of *in vitro* osteogenic differentiation of BMSCs and EPCs co-  
 801 cultured on electrospun SF membranes. (A) The expression of *ALPL* and *RUNX2* mRNAs  
 802 on day 7 and (B) *COL1A1* and *BGLAP* mRNAs on day 14, as detected by qRT-PCR. (C)  
 803 Representative Western blot images showing the abundance of ALP and RUNX2 proteins  
 804 on day 7 and (D) COL I and OCN proteins on day 14. (E, F) The quantitative analysis of  
 805 Western blot images in panels C and D. \*,  $p < 0.05$ ; ns, no significant difference.  $n=4$ .


806



807

808 **Figure 5.** Immunofluorescence images of COL I staining of BMSCs and EPCs co-  
 809 cultured on electrospun SF membranes. Staining was carried out on day 7 and day 14 of  
 810 after seeding cells. \*,  $p < 0.05$ ; ns, no significant difference.  $n=3$ .

811




812

813 **Figure 6.** Evaluation of the angiogenesis ability of BMSCs and EPCs co-cultured on  
 814 electrospun SF membranes. (A) The expression of *VEGF* mRNA was measured on day 3  
 815 and 5. (B) Protein expression of VEGF on day 3 and 5 detected by Western blot. (C)  
 816 Quantitative image analysis of VEGF Western blot. \*,  $p < 0.05$ ; ns, no significant  
 817 difference. n=4.

818


819



820

821 **Figure 7.** Immunofluorescence images of CD31 staining of BMSCs and EPCs co-  
 822 cultured on electrospun SF membranes. Staining was carried out on day 3 and 5 after  
 823 seeding cells. \*,  $p < 0.05$ ; ns, no significant difference. n=3.


824



825

826 **Figure 8.** *In vivo* bone repair. (A) Gross visual appearance of bone defects at 6 and 12  
 827 weeks after surgery. Red boxes mark the area of initial bone defects. (B) Representative  
 828 micro-CT 3D images (top row), longitudinal images (middle row) and cross-sectional  
 829 images (bottom row) of the radius of control, SF, SFM, and SFMC groups at 6 and 12  
 830 weeks. (C) BV/TV values in the different groups at 6 and 12 weeks. \*,  $p < 0.05$ ; ns, no  
 831 significant difference.  $n=3$ .





832

833 **Figure 9.** Microscopic features of new bone structures. Representative images of H&E  
834 staining of regenerative bone from different groups at 6 weeks (A) and 12 weeks (C) after  
835 implantation. Immunohistochemistry staining of COL I at 6 weeks (B) and 12 weeks (D)  
836 (n=3). SF indicates the transplantation of SF scaffolds alone. SFM: Scaffolds + cell free

837 electrospun SF membrane. SFMC: Scaffolds + cell contained SF membrane. Control

838 animals received no implants. IM, implanted material; NB, new bone.

839

840

841

Table 1. Primer sequences used for qRT-PCR.

<b>Gene</b>	<b>Forward (5'-3')</b>	<b>Reverse (5'-3')</b>
<i>COL1A1</i>	CAGGCTGGTGTGATGGGATT	CCAAGGTCTCCAGGAACACC
<i>ALPL</i>	TATGTCTGGAACCGCACTGAA	CACTAGCAAGAAGAAGCCTTT
<i>RUNX2</i>	ATCCAGCCACCTTCACTTACA	GGGACCATTGGGAACTGATAG
<i>BGLAP</i>	AACGGTGGTGCCATAGATGC	AGGACCCTCTCTCTGCTCAC
<i>VEGF</i>	CGAGTACATATTCAAGCCTTCC	CTTGCTCTGTCTTTCTTTGGTCC
<i>GAPDH</i>	ATGGTGAAGGTCGGAGTGAA	CCTCGCTCCTGGAAGATGGT

842